AMACR and prostate carcinoma: According to the results reported so far, target drugs that inhibit the expression of AMACR in prostate cancer are typically ibuprofenoyl-CoA derivatives (Petrova et al., 2019), and 2-(phenylthio)propanoyl-CoA derivatives (Yevglevskis et al., 2018).